Piramal Pharma Q1 FY25 net loss narrows

EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24

Emmes partners with Miimansa AI to accelerate adoption of Generative AI in clinical research

The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data

Fostering closer ties between industry & academia imperative for sustainable growth

The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future

Thyrocare Technologies posts Q1 FY25 consolidated profit at Rs. 24.17 Cr

Thyrocare Technologies has reported total income of Rs. 160.53 crores during the period ended June 30, 2024

Torrent Pharmaceuticals posts Q1 FY25 consolidated PAT at Rs. 457 Cr

Torrent Pharmaceuticals has reported total income of Rs. 2,883 crores during the period ended June 30, 2024

Zydus receives USFDA’s final approval for Valsartan Tablets

The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India

Alembic receives USFDA’s final approval for Fluphenazine Hydrochloride Tablets

Syngene reports drop in Q1 FY25 revenue to Rs. 790 Cr

Reported profit after tax declined 19% year-on-year to Rs 76 crores

Poly Medicure posts Q1 FY25 consolidated PAT at Rs. 74.03 Cr

Poly Medicure has reported total income of Rs. 401.69 crores during the period ended June 30, 2024

Solara Active Pharma Sciences reports Q1 FY25 consolidated loss at Rs. 13.46 Cr

Solara Active Pharma Sciences has reported total income of Rs. 364.05 crores during the period ended June 30, 2024